MetaCap

Amarin (AMRN) vs Assembly Biosciences (ASMB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Amarin (AMRN) has outperformed Assembly Biosciences (ASMB) over the past year, losing 35.5% versus a loss of 42.4%. Over five years, ASMB leads with a -21.3% price change compared with -85.5% for AMRN. Assembly Biosciences is the larger company by market cap ($454.4 million vs $444.4 million), about 1.0 times the size.

Assembly Biosciences converts more of its revenue into profit, with a net margin of -8.5% versus -18.2%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AMRN-35.47%ASMB-42.36%
+3%-24%-52%
Nov 21, 20251 yearNov 20, 2026
AMRN-86.45%ASMB-19.60%
+46%-25%-96%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AMRN versus ASMB key metrics
MetricAMRNASMB
Share price$10.57$22.19
Market cap$444.39M$454.39M
1-day change-6.13%-1.38%
YTD return-24.28%-34.75%
1-year return-35.47%-42.36%
5-year return-85.48%-21.31%
P/E ratio (TTM)—29.59
Forward P/E10.79—
EPS (TTM)$-0.80$0.75
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$213.65M$72.30M
Revenue growth (YoY)-6.55%+153.52%
Net income (latest FY)$-38.80M$-6.12M
Gross margin56.57%—
Operating margin-23.48%-16.76%
Net margin-18.16%-8.47%
52-week high$17.31$39.65
52-week low$10.56$19.20
Distance from 52-week high-38.94%-44.04%
Analyst consensusnonestrong_buy
Avg. price target upside+22.99%+130.73%
Average volume79.50K309.38K
Shares outstanding42.04M20.48M
Employees8073
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Assembly Biosciences is more profitable, keeping -8.5 cents of every revenue dollar as net income versus -18.2 cents for Amarin.
  • Assembly Biosciences grew revenue faster in its latest fiscal year (+153.52% vs -6.55%).

About Amarin

AMRN stock →

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees

About Assembly Biosciences

ASMB stock →

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection.

Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees

AMRN vs ASMB FAQ

Which is bigger, Amarin or Assembly Biosciences?

Assembly Biosciences (ASMB) is larger, with a market capitalization of $454.39M compared with $444.39M for Amarin (AMRN).

Which stock has performed better over the past year, AMRN or ASMB?

AMRN returned -35.47% over the past 12 months, compared with -42.36% for ASMB (price return, excluding dividends). Past performance does not predict future results.

Are Amarin and Assembly Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons